In brief
The West African nation stopped a $1.6 million hepatitis B vaccine study that would have withheld shots from half of 14,000 infants, sparking outrage from health experts and raising legal and ethical questions. A Danish research group led the trial, but the Guinea‑Bissau government paused the project in January and launched a review, followed in October by a judicial police raid that seized vaccine batches. The halt underscores the tension between pursuing innovative research and safeguarding public health and trust in government oversight.
Guinea‑Bissau halted a U.S.‑funded hepatitis B virus (HBV) vaccine trial for babies following backlash over the study’s design, a police raid on the research team’s facilities, and ongoing investigations into whether the trial met the country’s safety standards. The project, carried out by the Bandim Health Project—part of the University of Southern Denmark—sought to compare a birth‑dose schedule with a six‑week‑dose schedule in about 14,000 infants, an approach that critics said would withhold a lifesaving shot from half of the children.
The Bandim Health Project, led by Christine Stabell Benn and Peter Aaby, secured $1.6 million from the U.S. Centers for Disease Control and Prevention under Health Secretary Robert F. Kennedy, who has openly expressed anti‑vaccine views. According to Al Jazeera, the trial would have enrolled infants in Bissau beginning in December of the previous year, but the announcement sparked widespread anger from the medical community. A researcher involved in the project said in a statement that the end of the trial was a "significant setback" for African science.
In January the Guinea‑Bissau government paused the project and launched a review, citing a lack of necessary government approval and concerns over the ethical practice of withholding a vaccine from half of the study participants. Al Jazeera reported that the country’s judicial police conducted a raid on the Bandim Health Project’s facilities in Bissau in mid‑October, seizing vaccine batches and launching an inquiry into the trial’s compliance with national safety standards.
Officials have not commented on the raid or the ongoing investigation, leaving questions about the legal basis for the seizure and the extent of regulatory oversight. The lack of a formal government authorization for the study led to accusations that the research violated national protocols, a claim underscored by the medical community’s alarm that the trial could undermine public trust in child immunization programs.
The trial’s halt reveals the tension between the pursuit of international scientific collaboration and the duty to protect local populations from potential harm. By withholding a WHO‑recommended HBV vaccine from a portion of participating infants, the study was seen by critics as contravening basic ethical principles that prioritize the welfare of vulnerable populations, particularly newborns.
Beyond the immediate ethical concerns, the investigation raised by the judicial police underscores the importance of transparent regulatory mechanisms in a country that has historically faced challenges in public health governance. The seizure of vaccine batches illustrates a concrete action taken by authorities to reassert oversight, but it also highlights gaps in the systems that allow such a large‑scale study to proceed without clear governmental sanction.
The Bandim Health Project, which has operated in Bissau since 1978, has in the past conducted studies on thousands of Bissau‑Guineans and has focused on unintended vaccine impacts. Allegations that the researchers downplayed the vaccine’s risks have fueled mistrust and intensified calls for stronger safeguards.
The trial’s termination also raises broader civic stakes. With 14,000 infants originally slated to participate, the halting of the study means the country must consider how to address a potentially increased vulnerability to HBV infection—a disease that can lead to lifelong health complications. Public accountability will be tested as the government navigates the fallout from the incident and works to restore confidence in its health oversight.
In summary, Guinea‑Bissau’s decision to halt the controversial hepatitis B vaccine trial reflects a clash of scientific ambition and public protection. The development underscores the need for stringent national approval processes, clear ethical guidelines, and robust oversight when implementing large‑scale health interventions, particularly those involving infants. The ongoing investigation by the judicial police will determine whether the trial complied with the country’s safety standards, a verdict that will carry implications for future research policies and the role of international funding in local health initiatives.
